A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging drugs that activate the protein STING, substantially alter the activity of metabolic pathways responsible for generating the nucleotide building blocks for DNA.
Researchers found that alterations occur in cancer cells and can be visualized using FLT positron emission tomography (PET) imaging, marking the first time the effects of these drugs have been traced using a noninvasive imaging technique.
Understanding how STING agonists impact metabolic processes can help accelerate the clinical development of STING activating drugs in various therapeutic settings and guide the design of novel biomarkers and combination therapies.
